← Eichor
Study identifier: NCT07203599 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

A Study on the Treatment of Androgenetic Alopecia in Young Men With Umbilical Cord Mesenchymal Stem Cell Exosomes

Condition: Androgenic Alopecia  ·  Sponsor: Shenzhen People's Hospital

PhasePhase 1/Phase 2
Planned participants59
Who can joinMale, 18 Years to 35 Years
Healthy volunteersNo

About this study

This clinical trial aims to determine the efficacy of human umbilical cord mesenchymal stem cell exosomes (hUCMSC-sEV) in treating androgenic alopecia in young men. It will also investigate the safety of hUCMSC-sEV. The primary inquiry it seeks to address is: * Do hUCMSC-sEV demonstrate efficacy in the treatment of androgenic alopecia in young men? * Do hUCMSC-sEV safely used to treat androgenic alopecia in young men? The clinical trial has two parts. The Phase I study is a dose-escalation trial. Researchers will determine the appropriate dosage of hUCMSC-sEV. The Phase II study is a randomized controlled trial. Researchers will evaluate hUCMSC-sEV against a placebo (minoxidil tincture) to determine the efficacy of hUCMSC-sEV in treating androgenic alopecia in young men. In the phase I study, participants will be categorized into three dosage groups: A, B, and C. In Group A, one injection site will be allocated for each 1 cm² of hair loss area, delivering a dosage of 1.0×10\^8 particles per site. In Group B, the dosage will be 1.0×10\^9 particles per site. In Group C, the dosage will be 1.0×10\^10 particles per site. Participants will attend the clinic at weeks 0, 2, 4, and 6 for treatment and assessments. Participants will also attend the clinic for follow-up examinations at weeks 8, 12, and 24. In the phase II study, participants will be randomly allocated in a 1:1 ratio to two groups: the hUCMSC-sEV treatment group and the minoxidil treatment group. hUCMSC-sEV treatmen…

This description comes directly from the study's public registry record.

Talk to the study team

Jianglin Zhang, Ph.D  ·  +86 13873143466  ·  zhang.jianglin@szhospital.com

Zhenjun Deng, Ph.D  ·  +86 18487380167  ·  deng.zhenjun@szhospital.com

Always discuss trial participation with your own doctor first.

Locations (1)

Shenzhen People's HospitalShenzhen, Guangdong, ChinaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07203599